- Home
- EU vs STRO Comparison
EU vs STRO Comparison
Compare EU & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EU | STRO |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Other Metals and Minerals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.2M | 524.8M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | EU | STRO |
|---|---|---|
| Price | $1.61 | $28.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $4.00 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 2.8M | 291.3K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $43,155,000.00 | N/A |
| Revenue This Year | $212.11 | N/A |
| Revenue Next Year | $29.88 | N/A |
| P/E Ratio | $52.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.34 | $0.67 |
| 52 Week High | $4.19 | $43.85 |
Technical Indicators
Market Signals| Indicator | EU | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 42.12 |
| Support Level | $1.34 | $10.50 |
| Resistance Level | $2.17 | $43.85 |
| Average True Range (ATR) | 0.10 | 3.21 |
| MACD | 0.01 | -1.22 |
| Stochastic Oscillator | 65.00 | 22.83 |
Price Performance
Historical ComparisonAbout EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.